Hepatitis B virus (HBV) X protein (HBx) is considered to play a role in the development of hepatocellular carcinoma (HCC) during HBV infection. HCC was shown to be more prevalent in men than in women. Estrogen, which exerts its biological function through estrogen receptor (ER), can inhibit HBV replication. ERD5, an ERa variant lacking exon 5, was found to be preferentially expressed in patients with HCC compared with patients with normal livers. Here, we report the biological role of ERD5 and a novel link between HBx and ERa signaling in hepatoma cells. ERD5 interacts with ERa in vitro and in vivo and functions as a dominant negative receptor. Both ERa and ERD5 associate with HBx. HBx decreases ERa-dependent transcriptional activity, and HBx and ERD5 have additive effect on suppression of ERa transactivation. The HBx deletion mutant that lacks the ERa-binding site abolishes the HBx repression of ERa. HBx, ERa and histone deacetylase 1 (HDAC1) form a ternary complex. Trichostatin A, a specific inhibitor of HDAC enzyme, can restore the transcriptional activity of ERa inhibited by HBx. Our data suggest that HBx and ERD5 may play a negative role in ERa signaling and that ERa agonists may be developed for HCC therapy.
INTRODUCTION
Prolonged infection with Hepatitis B virus (HBV) has been clearly recognized as a major etiological factor for hepatocellular carcinoma (HCC) (1) . HBx, a virally encoded protein of 154 amino acids, has been shown to have multifunctional activities relevant to HBV-mediated oncogenesis (2) . HBx is involved in neoplastic transformation in cultured cells and can induce liver cancer in transgenic mice. Although HBx does not bind to double-stranded DNA, it regulates transcription of a variety of cellular and viral genes by interacting with cellular proteins and/or components of signal transduction pathways. HBx has been shown to interact with transcriptional factors such as RPB5 of RNA polymerase (3), TATA-binding protein (4) , basic region/leucine zipper (bZIP) proteins (5) and the tumor suppressor p53 (6) . Besides, it can also associate with serine protease TL2 (7) and cellular DNA repair protein (8) . The interaction of HBx with these proteins leads to activation of signal transduction pathways including the Ras/Raf/mitogen-activated protein kinase, protein kinase C, Jak1-STAT and nuclear factor kB pathways (9) (10) (11) (12) . However, the intracellular signaling pathways in which Hbx is involved are not fully elucidated.
Estrogen was shown to suppress HBV replication in male athymic mice transplanted with HBV-transfected HepG2 cells (13) . The fact that HCC is more prevalent in men than in women suggests that estrogen may play an important role in the development of HCC (14) (15) (16) (17) . Estrogen exerts its function through its two nuclear receptors, estrogen receptor a and b (ERa and ERb) (18) (19) (20) (21) . ERa and ERb share structural similarity characterized by several functional domains. Two distinct activation function (AF) domains, AF-1 and AF-2, located at the N-terminus and the C-terminus, respectively, contribute to the transcriptional activity of the two receptors. The DNA-binding domain (DBD) of the two receptors is well conserved and centrally located. Activation of ERs is responsible for many biological processes, including cell growth, differentiation and apoptosis.
ERa has been well characterized in human liver (22) . ERa is expressed in the liver of both healthy individuals and patients with HCC, with no differences in the pattern of expression (23, 24) . In contrast, the mutant form with the entire exon 5 deleted (ERD5) is preferentially expressed in patients with HCC compared with patients with normal livers (25) . The presence of the liver ERD5 transcript in the tumor was the strongest negative predictor of survival in operable HCC (26) (27) (28) . Its presence also correlates with a higher clinical aggressiveness of the tumor in comparison with tumors characterized by wild-type ERa (wt ERa) transcript. High rates of ERD5 expression have been shown to present in men at high-risk for HCC development. ERD5 encodes the hormone-independent AF-1 domain, as well as the DBD. Although ERD5 was demonstrated to be coexpressed with wt ERa in HCC, the role of ERD5 in ERa signaling remains to be investigated.
On the basis of in vivo and in vitro functional relevance of the estrogen/ERa axis and HBx in the development of HCC, we hypothesized that HBx may play a role in ERa signaling. Here, we show that ERD5 has a dominant negative activity in hepatoma cells when expressed together with wt ERa. HBx decreases ERa transcriptional activity, and HBx and ERD5 have additive effect on inhibition of ERa transactivation. We further present in vitro and in vivo evidence that both HBx and ERD5 interact with ERa. HBx inhibits ERa signaling possibly through recruitment of histone deacetylase 1 (HDAC1).
MATERIALS AND METHODS

Plasmids
The reporter constructs ERE-Luc (29), C3-LUC (30,31), pS2-LUC (32) and pS2DERE-LUC (33), and expression vector for ERa have been described previously. For the generation of FLAG-tagged full-length HBx, human HBx DNA was amplified by PCR using pHBV3091 as a template (34) . The amplified HBx DNA was cloned into pcDNA3 vector harboring FLAG epitope sequence (pcDNA3-FLAG). The deletion mutant of HBx (D73-120) was constructed by inserting the recombinant PCR-generated fragment from the HBx DNA into the pcDNA3-FLAG vector. The expression vectors for the full-length ERa (1-595), ERa AF1 (1-185), ERa DBD (180-282), ERa AF2 (282-595), ERa AF2 (302-595) and ERD5 (370 amino acids with a novel five-amino acid residue COOH terminus) were made by introducing the corresponding cDNAs into pcDNA3 (Invitrogen). Enhanced green fluorescent protein (EGFP)-tagged HBx construct was generated by inserting HBx DNA into pEGFP-C1 (Clontech), and red fluorescent protein (RFP)-tagged ERa construct by inserting ERa cDNA into pDsRed-N1 (Clontech). A cDNA fragment encoding entire coding region of HDAC1 was obtained by RT-PCR using as a template total RNA from the human hepatoma cell line HepG2, and the cDNA fragment was inserted in frame into a pcDNA3 vector linked with HA tag at the amino terminus. Plasmids encoding GST-fusion proteins were prepared by amplification of each sequence by standard PCR methods, and the resulting fragments were cloned in frame into pGEX-KG (Amersham Pharmacia Biotech) using appropriate restriction sites. All of the constructs were confirmed by sequencing. Details of cloning are available upon request.
Transfection and luciferase assay
HepG2 and SMMC-7721 cells were routinely grown in DMEM (Invitrogen) supplemented with 10% fetal bovine serum (FBS). For transfection, cells were seeded in 12-well plates containing phenol red-free DMEM medium supplemented with 10% charcoal-stripped FBS (Hyclone). The cells were transfected using Lipofectamine 2000 (Invitrogen) with 0.2 mg of ERE-LUC, C3-LUC, pS2-LUC or pS2DERE-LUC reporter plasmid, 50 ng of ERa expression plasmid, 250 ng to 2 mg of the expression vector for HBx and 0.1 mg of b-galactosidase reporter as an internal control. The empty vector pcDNA3 was used to adjust the total amount of DNA. After treatment with 10 nM of 17b-estradiol (E 2 ) and 100 nM 4-hydroxytamoxifen (4-OHT) for 24 h, or 100 nM trichostatin A (TSA) for 12 h, the cells were harvested, and luciferase and b-galactosidase activities were determined as described previously (35) . All experiments were repeated at least five times.
GST pull-down assay GST and GST-fusion proteins were expressed in E.coli DH5a, with the induction of protein expression performed at 20 C overnight (36) . After large-scale preparation, purification of the recombinant proteins were performed according to the manufacturer's instruction (Pharmacia) using glutathione-Sepharose beads. The expression plasmid for the ERa, ERa deletion mutants, HBx or HDAC1 was used for in vitro transcription and translation in the TNT System (Promega). The 35 S-labeled in vitro translated products were incubated with $10 mg of GST derivatives bound to glutathione-Sepharose beads in 500 ml binding buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.3 mM DTT, 0.1% NP-40 and protease inhibitor tablets from Roche) at 4 C. The beads were precipitated, washed four times with binding buffer, eluted in SDS-PAGE sample buffer, and analyzed by SDS-PAGE. After electrophoresis, the gel was dried and exposed to X-ray films.
Coimmunoprecipitation
HepG2 cells were transfected with the indicated plasmids using Lipofectamine 2000 (Invitrogen), washed with phosphate-buffered saline (PBS), lysed in 0.5 ml lysis buffer (50 mM Tris, pH 8.0, 250 mM NaCl, 0.25% NP-40, 1 mM DTT and protease inhibitor tablets from Roche), and immunoprecipitated with anti-FLAG-agarose beads (Sigma) for 3 h at 4 C. The beads were centrifuged, washed four times with the lysis buffer, and eluted in 30 ml of SDS-PAGE sample buffer. The eluted proteins were separated by SDS-PAGE, followed by immunoblotting with anti-ERa (Santa Cruz Biotech), anti-HA (Sigma) or anti-FLAG (Sigma) according to the standard procedures.
For reimmunoprecipitation, the immune complexes precipitated with anti-FLAG were eluted under native condition by a competition with 3· FLAG peptide according to the manufacturer's instructions (Sigma). The eluate was precleared with 20 ml of 50% protein A agarose beads (Santa Cruz Biotech) for 30 min. Proteins were reprecipitated with anti-ERa or control serum (Santa Cruz Biotech) plus 20 ml of protein A agarose beads. Reprecipitates were washed four times with lysis buffer, eluted by boiling in SDS-PAGE sample buffer, and resolved by SDS-PAGE, followed by immunoblotting.
For detecting interaction of endogenous HBx with ERa, liver tissue from an HBV positive patient (General Hospital of PLA, Beijing) was lysed in 1.0 ml RIPA buffer (PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and protease inhibitor tablets from Roche), and immunoprecipitated with anti-ERa or control serum (Santa Cruz). After extensive washing with RIPA buffer, the immunoprecipitates were resolved by SDS-PAGE, followed by western blot analysis using anti-HBx (Chemicon).
Confocal microscopy
HepG2 cells were seeded in 6-well dishes with glass coverslips containing phenol red-free DMEM medium (Invitrogen) supplemented with 10% charcoal-stripped FBS (Hyclone). Cells were transiently transfected with the indicated plasmids using lipofectamine 2000. Six hours after transfection, cells were treated with 10 nM of 17b-estradiol (E 2 ) for various times. Nuclear DNA was visualized with 4 0 ,6 0 -diamidino-2-phenylindole (DAPI). The subcellular localization of EGFP-HBx and RFP-ERa was analyzed with a Radiance 2100 confocal microscope (Bio-Rad). Fluorescence was detected with appropriate filter sets (the green signal, excitation 488 nm, dichroic mirror 560 DCLPXR, emission HQ 515/30; the red signal, excitation 543 nm, dichroic mirror 650 DCLPXR, emission HQ590/70).
RESULTS
Repression of ERa transcriptional activity by ERD5
To examine the effects of wt ER and the ER variant ERD5 on E 2 -responsive gene transcription, ERaÀnegative human liver carcinoma HepG2 cells (37) were transiently transfected with wt ERa and/or ERD5, along with the synthetic estrogenresponsive reporter plasmid ERE-LUC, or the natural estrogen-responsive reporters pS2-Luc and Complement 3-Luc (C3-Luc). As shown in Figure 1 , in the presence of E 2 , ERa stimulated the transcription of these reporter genes, whereas ERD5 had little effect. Importantly, when wt ER and ERD5 were co-transfected into the HepG2 cells in equal amounts, ERD5 was able to reduce the transcriptional activity of wt ER. These data suggest that ERD5 is able to interfere with the transcriptional activity of wt ER and to act as a dominant negative receptor.
Interaction of ERa with ERD5 in vitro and in vivo
The dominant negative property of the ER variant ERD5 could involve the formation of a heterodimer between ERD5 and wt ERa through protein-protein interactions. To test this possibility, GST pull-down experiments were performed in which in vitro translated 35 S-methionine-labeled ERD5 was incubated with full-length GST-ERa or GST. As shown in Figure 1B , in both the absence and presence of E 2 , ERD5 bound to GST-ERa, but not to GST, suggesting that ERa physically interacts with ERD5 in vitro.
To determine whether ERD5 interacted with ERa in vivo, HepG2 cells were transfected with ERa and FLAG-tagged ERD5, and grown both in the absence and presence of 10 nM E 2 . The cells were then subjected to immunoprecipitation (IP) with FLAG antibody-conjugated agarose beads, followed by immunoblot (IB) with ERa antibody, which recognizes both ERa and ERD5 proteins. As shown in Figure 1C , ERa could be co-immunoprecipitated in a ligandindependent manner in the presence, but not in the absence, of FLAG-ERD5. These results suggest that ERD5 interacts with ERa in hepatoma cells.
Repression of ERa transcriptional activity by HBx
To gain insight into the functional role of HBx in HCC, the effect of HBx protein on ERa transactivation function was investigated. HepG2 cells were co-transfected with the synthetic estrogen response element (ERE)-containing reporter ERE-LUC, ERa, and increasing amounts of HBx. Glutathione-Sepharose beads bound with GST-ERa or with GST were incubated with 35 S-labeled ERD5 in the absence or presence of 100 nM E 2 . After washing the beads, the bound proteins were eluted and subjected to SDS-PAGE and autoradiography. (C) In vivo interaction of ERD5 with ERa. ERa and FLAG-tagged ERD5 were co-transfected into HepG2 cells in the presence or absence of 10 nM E 2 . Cell lysates were immunoprecipitated (IP) by anti-FLAG M2 monoclonal antibody (Sigma), and the precipitates were then immunoblotted (IB) with anti-ERa polyclonal antibody (Santa Cruz Biotech).
As shown in Figure 2A , as little as 250 ng of HBx was sufficient to exert a potent repression of ERa transactivation function and the extent of repression increased with increasing amount of HBx expression, suggesting that HBx decreased ERa transcriptional activity in a dose-dependent manner. Similar repression was observed in other liver cancer cells such as SMMC-7721 (data not shown). It should be noted that the decreased transcriptional activity was not a result of reduced ERa protein production ( Figure 2B) .
To test the effect of HBx on natural estrogen-responsive promoter activity, HepG2 cells were co-transfected with the natural ERE-containing reporter C3-Luc or pS2-Luc, together with expression vectors for ERa and HBx. As shown in Figure 2C and D, activation of the C3 promoter by ERa was not affected by HBx, whereas activation of the pS2 promoter by ERa was significantly repressed by HBx, indicating that the effect of HBx is promoter specific. Interestingly, mutations of the EREs at the pS2 promoter abolished both the E 2 -dependent gene activation and HBx-mediated repression ( Figure 2E) . A similar repressive effect of HBx on ERa-mediated transcription was also observed in SMMC-7721 cells (data not shown). As another control of the effects of HBx on transcription, HBx stimulated Smad-mediated gene transcription as reported previously (38) , when HepG2 cells were co-transfected with the synthetic TGFb-responsive transcriptional reporter p3TP-Lux (data not shown). Taken together, our data suggest that specific cis-and trans-acting elements are required for the HBx-mediated repression.
Additive repression of specific ERa responsive gene transcription by HBx and ERD5
Since both HBx and ERD5 repressed ERa transcriptional activity, we determined if HBx and ERD5 had synergistic or additive effect on ERa transactivation. We co-transfected HepG2 cells with the ERE-Luc, C3-Luc, pS2-Luc or pS2DERE-Luc reporter construct, together with HBx or ERD5 or in combination. As expected, HBx alone inhibited the transcription of the ERE-Luc and pS2-LUC reporter genes but not the C3-Luc and pS2DERE-Luc reporter genes. ERD5 alone repressed the transcription of all of reporter genes except pS2DERE-Luc ( Figure 3A-D) . Cotransfection with HBx plus ERD5 expression vectors gave an additive effect in repressing the transcription of the pS2-LUC reporter gene but not the other reporter genes. These results indicate that the additive effect of HBx and ERD5 on ERa-responsive gene transcription is promoter specific.
To examine the effect of antiestrogen on suppression of ERa transactivation by HBx and ERD5, HepG2 cells were co-transfected with the pS2-Luc reporter, ERa, and HBx or ERD5 or in combination, and subsequently treated with the antiestrogen 4-OHT ( Figure 3E ). 4-OHT alone did not have significant effect on HBx-or ERD5-mediated repression, whereas combination of 17b-estradiol (E 2 ) and 4-OHT inhibited E 2 -induced ERa transactivation regardless of HBx and ERD5.
Interaction of HBx with ERa in vitro and in vivo
HBx has been shown to regulate viral and cellular gene transcription by interacting with transcription factors (3-6). Our observation that HBx could function as a co-repressor to repress ERa transactivation raised the possibility that HBx might physically interact with ERa. To test this possibility, GST pull-down experiments were performed using 35 S-labeled full-length ERa and GST-tagged full-length HBx. As shown in Figure 4A , GST-HBx, but not GST, was able to pull down the 35 Figure 4C ). In the negative control experiment, normal rabbit serum or an irrelevant antibody, anti-FLAG antibody, did not immunoprecipitate HBx ( Figure 4C and data not shown). Taken together, these data strongly suggest that HBx interacts with ERa in vivo.
Since HBx and ERD5 have additive effect on the ERa transactivation ( Figure 3C ), the effect of ERD5 on the HBx-ERa interaction was investigated. HepG2 cells were transfected with FLAG-tagged HBx, ERa, and increasing amounts of ERD5, and collected for coimmunoprecipitation assays. As shown in Figure 4D , Both ERa and ERD5 were coprecipitated with FLAG-tagged HBx, but not FLAG control vector. Consistent with the functional results ( Figure 3C ), ERD5 had little effect on the interaction of ERa with HBx ( Figure 4D ).
Co-localization of ERa with HBx
To confirm the protein-protein interaction between HBx and ERa in situ, constructs were made for EGFP-tagged HBx (EGFP-HBx) and RFP-tagged ERa. Based on their ability to regulate the ERE-Luc reporter activity, these fluorescent protein-tagged constructs were similar to those with or without the above mentioned FLAG tag (data not shown). HepG2 cells were then co-transfected with EGFP-HBx and RFPERa, and analyzed for co-localization of ERa with HBx. As expected, EGFP-HBx localizes in both the cytoplasm and the nucleus of HepG2 cells (39) (Figure 4E ). RFP-ERa localizes essentially in the nucleus of HepG2 cells in both the presence and absence of estrogen ( Figure 4E and data not shown). Co-localization studies indicated that EGFPHBx colocalized with RFP-ERa, but not with the empty vector RFP, predominantly in the cell nucleus in a ligandindependent manner, suggesting that ERa may facilitate the nuclear localization of HBx ( Figure 4E and data not shown).
Mapping of the ERa and HBx interaction regions
To define the interacting region(s) of HBx on ERa, GST-fusion proteins containing various regions of HBx were prepared and the ability of each of these to interact with 35 S-methionine-labeled in vitro translated full-length ERa were determined by GST pull-down assay ( Figure 4F ). Deletion of only the first 51 or last 11 amino acids of HBx did not affect the ability to interact with ERa. The GST-HBx(73-120) containing part of the transactivation domain bound specifically to ERa, but the GST-HBx(1-72) and the GST-HBx(121-154) did not.
To map the domain of ERa responsible for interaction with HBx, a series of 35 S-methionine-labeled in vitro translated ERa mutants were used in GST pull-down experiments ( Figure 4G ). The ERa(282-595) and the ERa(302-595) containing the AF2 domain were found to associate with HBx, whereas the ERa(1-185) containing the AF1 and the ERa(180-282) containing the DBD did not. ERD5, which has amino acid residues 1-365 of ERa also interacted with HBx, although with weak binding affinity.
Interaction of HBx with ERa is required for inhibition of ERa transactivation function
To test the possibility that the interaction of HBx with ERa is required for the repression of ERa transactivation function, the HBx mutant [HBx(D73-120)] in which the interaction region from amino acids 73 to 120 of HBx was deleted was constructed. HepG2 cells were co-transfected with the ERE-LUC reporter, ERa, and FLAG-tagged full-length HBx or HBx(D73-120). As shown in Figure 5A , the mutation lacking the ERa-binding site abrogated the repression of ERa transactivation function by HBx. Notably, FLAG-tagged HBx and HBx(D73-120) were expressed at comparable levels ( Figure 5B ). To determine if HBx(D73-120) did lose the ability to interact with ERa in HepG2 cells, coimmunoprecipitation experiments were performed. As expected, HBx(D73-120) did not interact with ERa ( Figure 5C ). Taken together, these findings suggest that interaction of HBx with ERa is required for repression of ERa transactivation function.
HBx, ERa and HDAC1 form a complex
To investigate whether the observed repression of ERaresponsive gene transcription by HBx was associated with recruitment of HDAC complexes, we examined the interaction between HBx and HDAC1 by GST pull-down assay. As shown in Figure 6A , in vitro translated HDAC1 interacted with GST-HBx, but not with GST alone, indicating that HBx associated with HDAC1 in vitro.
To determine whether the interaction of HBx with HDAC1 occurred in vivo, we performed coimmunoprecipitation and immunoblotting ( Figure 6B ). Transient expression of FLAG-tagged HBx, but not control FLAG vector, in HepG2 cells was accompanied by interaction with HAtagged HDAC1. These results suggest that HBx interacts with HDAC1 in vivo.
To examine whether HBx, ERa and HDAC1 formed a complex, HepG2 cells were transfected with ERa and HA-tagged HDAC1 with or without FLAG-tagged HBx. The cells were then subjected to immunoprecipitation with FLAG antibody-conjugated agarose beads, followed by immunoblot with ERa and HA antibodies ( Figure 6C ). Both ERa and HDAC1 were coprecipitated with FLAGtagged HBx, but not FLAG control vector. To further confirm the possibility of a ternary complex among HBx, ERa, and HDAC1, the immune complexes precipitated with FLAG antibody were eluted with a FLAG peptide, and subjected to a second immunoprecipitation with an anti-ERa antibody. The anti-ERa immunoprecipitates were then subjected to immunoblotting with anti-HA to detect HA-tagged HDAC1. HA-tagged HDAC1 was present after sequential immunoprecipitation ( Figure 6D ). In contrast, HA-tagged HDAC1 was absent after a second immunoprecipitation with control antibody. These data provide strong evidence that HBx, ERa and HDAC1 together can form a ternary complex in vivo.
HDAC inhibitor relieves repression of ERa transactivation function by HBx
Our observation that HBx interacts with HDAC1 raises the possibility that the repression of ERa functions by HBx could be HDAC dependent. To this end, we examined the effect of TSA, a specific inhibitor of HDAC enzyme, on HBx-induced repression of ERE transcription in HepG2 cells (Figure 7) . We found that HBx-mediated repression of ERa transcriptional activity could be effectively relieved by inhibiting HDAC activity. Interestingly, E 2 and TSA have additive or synergistic effect in stimulating ERa transcriptional activity. These data suggest that HBx may recruit HDAC enzyme to repress ERE-mediated transcription.
DISCUSSION
In the present study, we demonstrated for the first time that both ERD5 and HBx can inhibit ERa transcriptional activity Estrogen has been reported to promote the growth of certain human neoplasms, notably tumors of the breast, endometrium and pituitary (40, 41) . In sharp contrast, Estrogen was shown to suppress the replication of HBV that has been clearly recognized as a major etiological factor for HCC (13) . Studies of chemical carcinogenesis also The cell extracts were immunoprecipitated with anti-FLAG antibody. Immune complexes were eluted with FLAG peptide and re-immunoprecipitated (re-IP) using anti-ERa polyclonal antibody and normal rabbit serum as a negative control. The resulting precipitates were resolved by SDS-PAGE followed by immunoblotting with the indicated antibodies.
suggested that ERa may modulate HCC risk by inhibiting the malignant transformation of pre-neoplastic liver cells. The ERa variant ERD5 was shown to be preferentially expressed in patients with HCC compared with parents with normal livers and to be associated with poor clinical outcome (25) (26) (27) (28) . Therefore, it is important to determine whether the ERD5 is able to interfere with the transcriptional activity of wt ERa. When ERD5 was expressed alone in human ERa-negative hepatoma HepG2 cells, it had little effect on either basal or E 2 -mediated ERE-containing reporter activity. However, when ERD5 was coexpressed with wt ERa, the reporter activity was significantly decreased, similar to that in human breast cancer cells (42) . Our data suggest that ERD5 functions as a dominant negative receptor in human liver cancer cells. Although both in breast and liver cancer cells, ERD5 displays dominant negative activity, ERD5 was found to act as a dominant positive receptor isoform and facilitate both basal and E 2 -stimulated EREmediated transcription of wt ERa when coexpressed in ERa-negative human osteosarcoma U2-OS and human endometrial cancer Ishikawa cells (43, 44) . These discordant results could be due to the different cell types used, suggesting that some factors required for ERa transcriptional activity may be tissue specific.
A number of studies have shown that HBx interacts with proteins involved in transcriptional regulation (3) (4) (5) 45) . Most of the studies identify HBx as a co-activator of transcription. For example, HBx enhances the transcription efficacy of the CREB transcription factor through interaction with CREB (46) . HBx associates with hypoxia inducible factor-1a (HIF-1a), a major transcriptional factor that regulates expression of angiogenic factors such as vascular endothelial growth factor (VEGF), and enhances the transactivation function of HIF-1a (47, 48) . HBx was also shown to stimulate transcription by activating cellular signal transduction pathways. For instance, HBx is involved in activating Wnt/b-catenin signaling by stabilizing cytoplasmic b-catenin. HBx can stimulate activator protein 1 (AP-1) via two distinct pathways, the Ras-Raf-mitogen-activated protein kinase (MAPK) and the c-Jun amino-terminal kinase (JNK) cascades (49) . On the other hand, HBx was found to act as a co-repressor of transcription. HBx interferes with p53 by direct binding and by sequestering p53 in the cytoplasm, resulting in the abrogation of p53-mediated transcriptional activity (6) . HBx binds to DBD of peroxisome proliferator-activated receptor g (PPARg), a member of the steroid hormone receptor superfamily, and suppresses PPARg-mediated transactivation (50) . Our results showed that HBx represses ERa transcriptional activity through interaction with ERa and recruitment of HDAC1, which belongs to a class of enzymes involved in deacetylation of hyperacetylated histone tails, leading to compaction of chromatin and transcriptional repression (51) . Importantly, the inhibitory effect of HBx on ERa transcriptional activity was antagonized by the HDAC inhibitor TSA. Interestingly, E 2 and TSA are additive or synergistic in inducing ERa transcriptional activity. The fact that HBx represses ERa transcriptional activity in the presence or absence of E 2 suggests that HBx regulates ERa transcriptional activity in a ligand-independent manner. Recently, the tumor suppressor BRCA1 has been shown to mediate ligand-independent transcriptional repression of ERa in a manner dependent on HDAC activity (52) . Our observation that HBx, ERa and HDAC1 can form a complex and TSA can effectively reverse ligand-independent repression mediated by HBx suggests that one of the underlying mechanisms by which HBx mediates ligand-independent repression of ERa transcriptional activity may involve targeted recruitment by unliganded, promoter-bound ERa of a HBx-associated HDAC activity.
Tamoxifen is considered to be relatively more estrogenic than antiestrogenic in the urine, bone and liver tissues (37) . Thus, tamoxifen has been used for the treatment of liver cancer. Indeed, initial studies with a relatively small population of patients with HCC show regression of liver tumor mass and improved survival in some of the tamoxifen-treated patients (53) . However, more and more recent controlled trials with this drug were disappointing (54-56). Tamoxifen does not prolong survival in patients with HCC and has an increasingly negative impact with increasing dose. There is also no appreciable advantage to quality of life with tamoxifen. These studies showed conclusively that, although the mechanisms by which tamoxifen negatively impacts HCC are not known, tamoxifen does not benefit patients with HCC and is likely to be detrimental. Thus, the use of tamoxifen in patients with HCC is not recommended. Our study indicated that 4-OHT, a metabolite of the tamoxifen with a more potent estrogen agonist/antagonist activity than tamoxifen, acts as a pure estrogen antagonist in HepG2 cells, which is in agreement with the previous study showing that tamoxifen functions as a pure estrogen antagonist in HepG2 cells (37) . This may at least in part explain why tamoxifen is ineffective in the treatment of HCC.
Recently, HDAC inhibitors have been used successfully to inhibit cancer cell growth in vitro and in vivo (57-59). TSA specifically inhibits classes I and II HDACs by binding directly to their catalytic site (3) . Class I HDACs include HDAC1, HDAC2, HDAC3, HDAC8 and HDAC11, and Class II HDACs include HDACs 4-7 and HDACs 9-10. TSA regulates the expression of small subsets of growthrelated genes and has potent antitumor activity in vitro and in vivo. In hepatoma cells, TSA induces a G 2 /M cell cycle arrest followed by apoptosis (60, 61) . Since E 2 and TSA are additive or synergistic in inducing ERa transcriptional activity in hepatoma cells, it is important to develop more effective therapeutic agents for HCC that increase ERa transactivation function, with no obvious side effects.
